louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05403996: Effects of an Active Break Program at Primary School
Official title: Effects of an Active Break Program at School on Physical Activity and On-task Behavior in Children From 6 to 12 Years Old
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Health Behavior
Behavior, Child
Keywords: physical activity
physical activity enjoyment
on-task behavior
Lead sponsor: Universidad de La Frontera
Sponsor class: OTHER
Collaborators: name: Playa Ancha University
name: Universidad Metropolitana de Ciencias de la Educacion
First posted: 2022-06-03
Enrollment: 60
Sex: ALL
Minimum age (years): 8
Maximum age (years): 10
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Pilot cluster randomized controlled trial
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the effectiveness of an active break program at school on physical activity levels and enjoyment, and on-task behavior in children.

Detailed description: The protocol will include third and fourth-grade students (children aged 8 to 10 years) from elementary schools in the Valparaíso Region, Chile. Four school classes from two schools (intervention and control school) will be included. The intervention school will carry out the active break program, ACTIVA-MENTE This program consists of the application of a 4-and-a-half-minute video with moderate to vigorous-intensity physical activity. These breaks will take place 6 times a day in classes for 6 weeks.

Eligibility criteria: Inclusion Criteria:

* Schoolchildren aged 8 to 10 years old (third to fourth grade of primary education).

Exclusion Criteria:

* Children with school attendance lower than 90 per cent (excluded from data analysis).
* Any medical condition that impedes physical activity breaks.

Primary outcomes:
measure: Physical activity
timeFrame: 6 weeks
measure: On-task behavior
timeFrame: 6 weeks
Secondary outcomes:
measure: Physical activity enjoyment
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Valparaíso
country: Chile
facility: Facultad de Ciencias de la Actividad Física y del Deporte
Study officials:
affiliation: Playa Ancha University
name: Tomas Reyes, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01412996: Quality of Life Measures After Single Access Vs Conventional Laparoscopic Cholecystectomy: Prospective Randomized Study.
Official title: Single Access Laparoscopic Cholecystectomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Evidence of Cholecystectomy
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2011-08-09
Enrollment: 250
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aimed to compare the short term outcomes between SALC and conventional laparoscopic cholecystectomy (CLC).

Detailed description: In a prospective study, two hundred fifty patients with symptomatic gall bladder stone were randomized to SALC or conventional laparoscopic cholecystectomy (CLC) (125 in each group). The primary endpoint of this study was to assess the total outcomes of quality of life using EuroQoL EQ-5D questionnaire. The secondary endpoints were postoperative pain, analgesia requirement and duration, operative time, perioperative complications, estimated blood loss, hospital stay, cosmoses outcomes and number of days required to return to normal activities.

Eligibility criteria: Inclusion Criteria:

* GALL BLADDER STONES

Exclusion Criteria:

* ACUTE CHOLECYSTITIS
* PREVIOUS LAPAROTOMY
* ASA ABOVE 3

Primary outcomes:
measure: QUALITY OF LIFE
timeFrame: PREOPERATIVEELY, after 1 WEEK, 1 and 6 months postoperative
Secondary outcomes:
measure: operative time
timeFrame: 2 hours
measure: postoperative pain
timeFrame: 5 days
measure: days to return to normal activity (RTNA)
timeFrame: 10 days
measure: COSMOSIS OUTCOMES
timeFrame: 1 AND 6 MONTHS
measure: ANALGESIC REQUIRMENT
timeFrame: POSTOPERATIVE PERIOD
Other outcomes:
Locations:
city: Mansoura
country: Egypt
facility: Mohamed Abdellatif
Study officials:
affiliation: Mansoura University
name: RAMADAN ELLITHY, MD
role: STUDY_CHAIR
References:
Clinical trial NCT06675396: Pharmacogenomics of Mood Disorder in Chronic Kidney Disease Patients
Official title: Cohort Study on the Psychiatric Outcomes and Genetic Associations in Patients With Chronic Kidney Disease
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Chronic Kidney Disease(CKD)
Depression
Keywords: CKD
Mood disorder
Lead sponsor: Wonju Severance Christian Hospital
Sponsor class: OTHER
First posted: 2024-11-05
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with CKD without history of mood disorder

Brief summary: By using genetic information we could predict the prevalence of mood disorder and response to treatment.

Detailed description: This prospective cohort study enrols patients with chronic kidney disease and gathers genetic information. By the patient's biochemical information, including genetic information, we could predict the prevalence of mood disorder and response to the antipsychotherapy.

Eligibility criteria: Inclusion Criteria:

* CKD patients aged 18 to 90 years

Exclusion Criteria:

* no CKD patients, aged below 18 or above 90 years

Primary outcomes:
measure: Prevalence of depression
timeFrame: 10 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01840696: Phase Analysis and Obstructive CAD on Rubidium PET
Official title: Regional and Global Left Ventricular Mechanical Dyssynchrony in the Diagnosis of Obstructive Coronary Artery Disease on Rest and Regadenoson Stress Rubidium Myocardial Perfusion PET
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Coronary Artery Disease
Lead sponsor: Emory University
Sponsor class: OTHER
First posted: 2013-04-26
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Rubidium myocardial perfusion PET is an imaging test used to diagnose patients with abnormal blood flow to the heart secondary to narrowing of the heart vessels.

Phase analysis is a computer method that is applied after the PET test is done. It is used to determine when a region of the heart contracts relative to other heart regions in the heart beating cycle. Initial data suggest that regions of the heart with abnormal blood flow change the pattern of contraction from rest to stress conditions. That is, regions of the heart with abnormal blood supply become dyssynchronous when compared to the normal regions of the heart.

This study will investigate whether phase analysis may aid the visual interpretation of rubidium myocardial perfusion PET studies by determining the areas of the heart that are not beating in synchrony with the normal heart regions. This information will be used as a proxy for poor blood supply. The gold standard will be coronary angiography by which the percent narrowing of the heart vessels is assessed.


Eligibility criteria: Inclusion Criteria:

* Male or female patients
* referred for myocardial perfusion imaging for suspected obstructive CAD
* 18 years of age or older.

Exclusion Criteria:

* Contraindications to regadenoson radionuclide imaging including severe reactive airway disease, unstable crescendo angina, high grade AV block, caffeine within 24 hours
* Documented prior myocardial infarction
* Severe claustrophobia
* Patients who may be pregnant.

Primary outcomes:
measure: Stress/rest differences in global left ventricular mechanical contraction bandwidth.
timeFrame: Up to 12 months
Secondary outcomes:
measure: Stress/rest differences in segmental left ventricular mechanical contraction bandwidth.
timeFrame: Up to 12 months
Other outcomes:
Locations:
city: Atlanta
country: United States
facility: Emory University Hospital
state: Georgia
Study officials:
affiliation: Emory University
name: Fabio Esteves, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06905496: Apnea of Prematurity Results in Respiratory Distress and Cyanosis. Caffeine Citrate Can Treat It.
Official title: Comparison of Outcomes of High Dose Verses Low Dose Caffeine Citrate in the Treatment of Apnea of Prematurity
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
Conditions: Apnea of Prematurity
Keywords: caffeine citrate
apnea
prematurity
Lead sponsor: Nishtar Medical University
Sponsor class: OTHER
First posted: 2025-04-01
Enrollment: 114
Sex: ALL
Minimum age (years): 1
Maximum age (years): 10
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: High-dose caffeine citrate is more effective than low-dose caffeine citrate in the treatment of apnea of prematurity (AOP). The high-dose group showed fewer apnea episodes, higher extubation success rate, lower extubation failure rate and shorter duration of oxygen therapy

Detailed description: Apnea of prematurity (AOP) is a common condition in preterm infants due to immature respiratory control, affecting up to 80% of those under 1000 grams. It can lead to serious complications, including respiratory distress, pulmonary hemorrhage, and developmental delays. Caffeine citrate, a methylxanthine, is widely used for AOP treatment due to its longer half-life and better absorption compared to theophylline. However, the optimal dosage remains uncertain, with varying practices globally.

Eligibility criteria: Inclusion Criteria:

* • Patients with a gestational age of ≥32 and \<37 weeks at birth on LMP.

  * Diagnosis of apnea of prematurity (AOP) established as per operational definition within the first 10 days of life.
  * Either male or female patients

Exclusion Criteria:

* • Patients diagnosed with Hydrops fetalis (evaluated through medical record).

  * Patients presenting with major congenital or chromosomal anomalies such as anencephaly, spina bifida, congenital heart defects (e.g., tetralogy of Fallot, transposition of the great arteries), or chromosomal disorders (e.g., trisomy 18, Turner syndrome).
  * Presence of a confirmed sepsis through blood culture.
  * Presence of a significant underlying neurological disorder evaluated by history and medical records that could contribute to apnea (e.g., intraventricular hemorrhage with posthemorrhagic hydrocephalus, hypoxic-ischemic encephalopathy)
  * Patients who have been previously treated with caffeine or other methylxanthines for apnea.

Primary outcomes:
measure: Enhanced Respiratory Stimulation, Effect of Caffeine Citrate on the stimulation of respiratory system of premature individuals
timeFrame: 2-3 days after starting the intervention
Secondary outcomes:
Other outcomes:
Locations:
city: Multan
country: Pakistan
facility: Nishtar Medical Hospital, Multan
state: Punjab
Study officials:
affiliation: Nishtar Medical University
name: Fatima Zahra, FCPS
role: STUDY_CHAIR
References:
Clinical trial NCT04279496: Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry
Official title: Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter
Study type: OBSERVATIONAL
Overall status: ENROLLING_BY_INVITATION
Conditions: Coronary Artery Disease
Lead sponsor: Cleerly, Inc.
Sponsor class: INDUSTRY
First posted: 2020-02-21
Enrollment: 35000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: OTHER
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with stable coronary artery disease

Brief summary: The overall objective of CONFIRM2 is to perform the largest cardiovascular phenotype outcomes study ever.

Detailed description: CONFIRM2 is a retrospective and prospective, open-label, international, multicenter observational registry designed to evaluate associations between CCTA imaging findings and clinical presentation (cross-sectional) and their ability to predict mortality and major adverse cardiac events (longitudinal) in patients with chronic CAD.

Eligibility criteria: Inclusion Criteria:

* Age \>18 years
* Undergoing clinically indicated CCTA with \>64-detector row CT
* Signed informed consent, including of release of medical information, long term follow-up and Health Insurance Portability and Accountability Act (HIPAA) documentation

Exclusion Criteria:

* Individuals unable to provide informed consent
* Non-cardiac illness with life expectancy \< 2 years
* Pregnancy

Primary outcomes:
measure: Coronary CT Angiography EvaluatioN For Clinical Outcomes
timeFrame: June 2020- June 2022
Secondary outcomes:
Other outcomes:
Locations:
city: Charlottesville
country: United States
facility: University of Virginia
state: Virginia
Study officials:
affiliation: Cleerly, Inc.
name: James K Min, MD
role: STUDY_CHAIR
affiliation: UVA
name: Todd Villines, MD
role: STUDY_CHAIR
References:
Clinical trial NCT05112796: Vestibular Socket Therapy (VST) Versus Partial Extraction Therapy
Official title: Vestibular Socket Therapy (VST) Versus Partial Extraction Therapy (PET) for Treating Fresh Extraction Sites With Thin Labial Plate of Bone With Immediate Implant Placement in the Esthetic Zone: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dental Implants
Lead sponsor: Alexandria University
Sponsor class: OTHER
First posted: 2021-11-09
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The current randomized clinical trial aimed to compare the VST versus Partial Extraction Therapy (PET) for immediate implant placement in the esthetic zone in class I fresh extraction sites.

The primary outcome was the assessment of vertical dimensional changes in peri-implant soft tissue margin.

The secondary outcome was the assessment of radiographic changes in the thickness of the facial peri-implant tissues.


Eligibility criteria: Inclusion Criteria:

* single hopeless maxillary tooth in the esthetic zone
* non-smokers
* systemically healthy
* Class I extraction sites

Exclusion Criteria:

* smoking
* Class II and III extraction sites
* hopeless teeth with acute infection or vertical/horizontal root fracture

Primary outcomes:
measure: Changes in the peri-implant facial tissue thickness
timeFrame: at baseline and 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Alexandria
country: Egypt
facility: Private Practice Clinic
Study officials:
References:
Clinical trial NCT01727596: The Effects and Predictors of Patella Taping in the Treatment of Patellafemoral Pain Syndrome
Official title: The Effects and Predictors of Patella Taping in the Treatment of Patellafemoral Pain Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Patellofemoral Pain Syndrome
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2012-11-16
Enrollment: 100
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Background: Taping has been used for more than 20 years for patellofemoral pain syndrome (PFPS) but the effectiveness is still controversial.

Purpose: This prospective study was conducted to investigate the effect and predictors of effectiveness of taping in treating PFPS.

Study design: Prospective cohort study Methods: One hundred consecutive patients with the diagnosis of PFPS were included in the study. Factors including sex, age, body mass index (BMI), Q angle, lateral patella displacement (LPD), lateral patellofemoral angle (LPA) and pre-taping pain score were measured. One well-trained therapist applied adhesive tape to each patient by McConnell approach. Before and after taping, patients completed a visual analog pain scale (VAS) after performing a step-down from an 8-inch platform. Paired-t test was used for the difference of the VAS score measured before and after taping. Patients with improvement of more than 1 point in VAS score after taping were considered responsible, and others were non-responsible. The results were analyzed by logistic regression.


Eligibility criteria: Inclusion Criteria:

* (1) between the age of 20 to 60 years, (2) antero-, retro-, or peri-patellar pain from at least two of the following: prolonged sitting, ascending or descending stairs, prolonged walking, squatting, and (3) insidious onset of symptoms unrelated to a traumatic incident.

Exclusion Criteria:

* (1) symptoms or signs of any intrarticular derangement of the knee joint, such as effusion, ligament laxity, and meniscal tear, (2) tenderness over the patella tendon, iliotibial band, or pes anserinus tendons, (3) Osgood-Schlatter disease or Sinding-Larsen-Joahanssen syndromes, (4) referral pain from hip or lumbar region, (5) a history of patellar dislocation, previous knee surgery or infection, (6) malignancy, (7) present pregnancy, (8) recent treatment for the PFPS, such as physiotherapy, non-steroid anti-inflammatory or corticosteroid medication, (9) advanced osteoarthritis of the knee joint.

Primary outcomes:
measure: VAS score
timeFrame: two weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: NTUH
Study officials:
affiliation: National Taiwan University Hospital
name: Ching-Chuan Jiang, M.D. PHD
role: STUDY_CHAIR
References:
Clinical trial NCT01961596: The Influence of a "Cooling Ice Spray " Application on the Time to Stability After a Forward Jump?
Official title: Does Have a Short-term "Cooling Ice Spray" Application at the Lateral Ankle an Influence on the Time to Stability After a Forward Jump?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Keywords: Cooling ice spray
Time to stability
Jump
Lead sponsor: Balgrist University Hospital
Sponsor class: OTHER
First posted: 2013-10-11
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: The aim of this study is to investigate the influence of a brief application of cold (by means of Cooling Ice Spray on the lateral ankle)on the time to stabilization of healthy subjects.

Detailed description: In sports are "Cooling Ice Spray" applications after an injuries one of the most common and popular methods used. It is very popular mainly because of its analgesic effect and easy application. It is assumed that such application will not affect the athletes. Nevertheless after an application of cold a reduced nerve conduction velocity was measured, resulting in a reduction in pain and a reduced transmission rate. Usually the static equilibrium or the perception of joint position was investigated and not the time to stability. As far as we have been known so far been no study that has examined the impact of a brief application of cooling ice spray on the time to stability after dynamic function. Therefore this study what's to investigate the influence of "Cooling Ice Spray" on the time to stability after a forward jump.

Eligibility criteria: Inclusion Criteria:

* healthy adults
* 18-45 age
* \>3 Score "Tegner-Activity-Scale"

Exclusion Criteria:

* Cognitive deficits
* Physical disability
* Pain
* Injuries in the previous 6 weeks
* Non healed injuries at the leg
* Allergic reaction from cooling ice pray

Primary outcomes:
measure: Time to stability
timeFrame: All measurements will be executed within 1hour. After 2 days the measurements will be repeated
Secondary outcomes:
measure: Skin temperature
timeFrame: All measurements will be executed within 1hour. After 2 days the measurements will be repeated
measure: Side step time to stability
timeFrame: All measurements will be executed within 1hour. After 2 days the measurements will be repeated
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: Balgrist Univeresty Hospital
state: ZH
Study officials:
affiliation: Balgrist Univeresty Hospital
name: Jaap Swanenburg, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05974696: A Research Registry on Aggressive PitNETs
Official title: A Research Registry on Aggressive PitNETs
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Endocrine Tumor
Keywords: Endocrine Tumor
Reference centre
rare diseases
transcriptoms
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2023-08-03
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adult subjects with pituitary tumours whose file is presented to the national HYPOcare RCP. There is only one group.

Brief summary: To allow the identification of markers, it is necessary to extend research networks more widely to collect and properly explore aggressive pituitary tumours. The multidisciplinary consultation meeting (RCP), organised by the reference centre for rare diseases of the pituitary gland, dedicated to aggressive pituitary tumours and carcinomas (HYPOcare), which is unique in France and brings together national experts, currently makes it possible to orientate the management of patients with an aggressive pituitary tumour. With more than 80 patient files discussed since its inception, the patient cohort via the HYPOcare RCP is one of the largest both nationally and internationally. At present, this data source is only dedicated to the clinical management of the files without the possibility of carrying out research work


Eligibility criteria: * Inclusion Criteria :

  * Patients with a diagnosis of pituitary tumour
  * Patients whose file has been presented to the national HYPOcare RCP
* Exclusion Criteria :

  * Patients objecting to participating in this research

Primary outcomes:
measure: Characterisation of aggressiveness of pituitary tumours by tanscriptome analysis
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Lyon
country: France
facility: Hospices Civils de Lyon - Groupement Hospitalier Est
Study officials:
References:
Clinical trial NCT00202696: Nalmefene Smoking Cessation Study
Official title: A Single Center Evaluation of Nalmefene HCl Versus Placebo on Smoking Cessation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Smoking Cessation
Lead sponsor: Somaxon Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2005-09-20
Enrollment: 76
Sex: ALL
Minimum age (years): 25
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To determine if nalmefene is safe and effective in smoking cessation.

Detailed description: Single centered, randomized, placebo-controlled,double-blind, outpatient pilot study to evaluate the efficacy, safety and tolerability of 2 doses of nalmefene on smoking cessation.

Eligibility criteria: Inclusion Criteria:

* Smokers in good general health self reporting more than 15 cigarettes per day

Exclusion Criteria:

-

Primary outcomes:
measure: Assess the efficacy of 2 doses of nalmefene relative to placebo
Secondary outcomes:
measure: Evaluate the safety and tolerability of 2 doses of nalmefene
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Somaxon Pharmaceuticals CMO
name: Philip Jochelson, MD
role: STUDY_DIRECTOR
References: